The common thread to DiGA and DiPA
One partner from idea to commercial scale.
Idea & Feasibility
Does your idea fit the DiGA/DiPA framework? We assess it and plan the path.
BfArM Advisory
We prepare your consultation meeting, including a study synopsis, and accompany you.
Robust Concept
Evidence strategy, study protocol, and study report from a single source.
BfArM Application
BfArM application from start to finish with rapid deficiency-letter handling.
Commercial Scale
Price negotiation, launch plan, and commercial execution after listing.
Alongside: Medical Writing
Publications and conference abstracts for your study — across all phases.
Alongside: our network
Proven partners in regulatory affairs, CROs, law and investment that we know and value. Access to conversations with the GKV on §140a contracts.
Four reimbursement pathways
Each pathway has its own evidence requirements, timeline, and economics.
DiGA (MDR Class I and IIa)
What it is
Prescription digital therapeutics (DTx) for all indications in the ICD catalogue, listed by BfArM and reimbursed by statutory health insurance for 74 million people in GER.
Why it matters
Germany is (next to France and Switzerland) the only market with scalable reimbursement for digital therapeutics in the world and the fastest route to reimbursed revenue in Europe.
Latest
The first DiGA crossed >€50M in annual reimbursement revenue in 2025: the market has moved from proof-of-concept to commercial scale.
Oviva has shown that annual revenue of more than €50M with a DiGA is possible. We believe this kind of success is also possible in other indications.
Jonas Albert
Co-Managing Director · hippocamp
The DiGA experts at hippocamp
Countless years of DiGA and healthcare experience compressed into one team.
Co-Managing Director — DiGA Commercial
Julian Gansen
>10 years in healthcare, >6 in DiGA leadership roles. Listed DiGAs and successfully scaled DiGA revenue.
CO-MANAGING DIRECTOR — DIGA STRATEGY
Jonas Albert
>10 years in healthcare, >6 in DiGA leadership roles. Supported more than half of all successful DiGA listings.
Consultant — DiGA Listing
Lena Fink
>5 years in DiGA evidence and application support; led successful manufacturer-side filings.
Principal — DiGA Evidence
Dr. Patrick Timpel
>10 years in health technology assessment and care research; leading expert in DiGA studies and evidence strategy.
Bring us in at any stage: we will make a difference.
Scoping a DiGA, prepping a BfArM submission, or staring at a deficiency letter at midnight: our experience cuts through months of back-and-forth and gets you to the right answer fast.